The pathogenesis of osteoporosis

Area of Science:

• Endocrinology
• Gerontology
• Bone Metabolism

Background:

• Age-related hormonal changes significantly contribute to osteoporosis pathogenesis.
• Reduced serum 1,25-dihydroxyvitamin D and calcium malabsorption are common in postmenopausal (Type I) and senile (Type II) osteoporosis.
• Different hormonal pathways underlie Type I and Type II osteoporosis, both resulting in bone loss.

Purpose of the Study:

• To elucidate the role of calciotropic hormones in osteoporosis.
• To investigate the mechanisms of calcium malabsorption in different osteoporosis types.
• To evaluate the therapeutic potential of vitamin D analogues in managing osteoporosis.

Main Methods:

• Analysis of calciotropic hormone levels in relation to age and osteoporosis.
• Assessment of calcium absorption and balance.
• Evaluation of vitamin D analogue therapy effects on bone metabolism and fracture incidence.

Main Results:

• Type I osteoporosis involves reduced parathyroid hormone, decreasing 1,25-dihydroxyvitamin D and calcium absorption.
• Type II osteoporosis is characterized by declining renal 1 alpha-hydroxylase activity, leading to reduced 1,25-dihydroxyvitamin D, calcium malabsorption, and secondary hyperparathyroidism.
• Vitamin D analogue treatment normalizes calcium absorption, improves calcium balance, reduces bone resorption, and lowers fracture rates.

Conclusions:

• Age-related calciotropic hormone dysregulation is a key factor in osteoporosis development.
• Vitamin D analogues effectively improve calcium homeostasis and mitigate bone loss.
• Therapy with vitamin D analogues offers a promising strategy for reducing fracture incidence in osteoporosis.